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Sugammadex is a modiﬁed type of g-cyclodextrin containing 8
thiopropionate side chains. It is used for the safe and rapid reversal
of neuromuscular block, such as rocuronium or vecronium.1
Although several cases were reported as intraoperative anaphylaxis
caused by sugammadex, the causative epitopes have not fully un-
derstood yet. Here, we present a case of anaphylaxis caused by
the g-cyclodextrin in sugammadex.
A 65-year-old woman underwent an endoscopic left paranasal
sinus operation for a left maxillary cyst. She had undergone surgery
for ileus 15 years ago. She had no history of food, drug or other al-
lergies and had not been exposed to sugammadex previously. At
the end of the operation, 200 mg sugammadex were administered
to reverse a rocuronium-induced neuromuscular block. Two mi-
nutes later, she developed hypotension (systolic arterial pressure:
<60 mm Hg), and erythema over her whole body. After the admin-
istration of ephedrine and hydrocortisone sodium succinate, her
symptoms improved. Drug-induced anaphylaxis was suspected.
Two months later, we performed prick tests and intradermal
tests based on the drugs and latex gloves used in the operation
before the onset of anaphylaxis; i.e., we tested the effects of sugam-
madex (0.01, 0.1, 1, and 10% aq.), lidocaine hydrochloride, ﬂurbipro-
fen axetil, fentanyl citrate, acetaminophen, propofol, and latex. The
patient's responses to the prick tests and intradermal tests were
examined after 15 min and were graded according to the standard
method reported by Dresborg et al.2 A response of grade 2 or
greater that was stronger than the patient's response to the nega-
tive control was considered to be positive. We also performed prick
tests with saline as a negative control and histamine (10 mg/ml) as
a positive control, and an intradermal test with saline as a negative
control. The prick tests produced negative reactions for all agents.
However, the intradermal test with 0.01% (aq.) sugammadex pro-
duced a grade 1 reaction, and that with 0.1% (aq.) sugammadex eli-
cited a grade 2 reaction (an erythematous lesion measuring
28.3  32.8 mm and a wheal measuring 9.1  9.6 mm) (Fig. 1A).
All of the other substances produced negative results. Anaphylaxis
caused by sugammadex was subsequently diagnosed. Although the
prick tests produced negative reactions for sugammadex, the intra-
dermal test with it produced a positive reaction. That seemed to be
because the dose of antigen absorbed into the skinwas larger in the
intradermal test than that in the prick test.
Sugammadex is a modiﬁed form of g-cyclodextrin containing 8
thiopropionate side chains (Fig. 2A),1 so we then examined which
epitope of sugammadex had induced the allergic reaction. To thePeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).best of our knowledge, the optimal concentrations of g-cyclodex-
trin (Fig. 2B) for use during prick tests and intradermal tests have
not been reported in the literature, so we performed the g-cyclo-
dextrin prick tests using the same concentration as were employed
during the sugammadex prick tests (0.01, 0.1, 1, and 10% aq.), and
the same approach was adopted for the intradermal tests of g-
cyclodextrin (0.001 aq. and 0.01% aq.; Wako, Japan). We also per-
formed prick tests with methyl 3-mercaptopropionate (0.001% aq.
and 0.01% aq.; Wako) (Fig. 2C) and ethyl 3-methylthiopropionate
(0.001% pet. and 0.01% pet.; Wako) (Fig. 2D), which are found in thi-
opropionate. All of the prick tests produced negative reactions. The
intradermal test of 0.01% (aq.) g-cyclodextrin elicited a
grade ± reaction, and that of 0.1% (aq.) g-cyclodextrin produced a
grade 2 reaction (an erythematous lesion measuring
24.7  25.7 mm and a wheal measuring 6.0  6.1 mm) (Fig. 1B).
The intradermal test of saline produced negative results. Intrader-
mal tests of g-cyclodextrin (0.1% aq.) did not produce any reactions
in three normal subjects. We did not perform intradermal tests
with methyl 3-mercaptopropionate because it irritates the skin,
or with ethyl 3-methylthiopropionate due to its insolubility in wa-
ter. Based on these ﬁndings, anaphylaxis due to the g-cyclodextrin
in sugammadex was diagnosed. As g-cyclodextrin contains 8
glucose units, and a- and b-cyclodextrin contain 6 and 7 glucose
units, respectively (Fig. 2E, F),3 we also performed prick tests
with a-cyclodextrin (10% aq.; Wako), b-cyclodextrin (10% pet.;
Wako), and intradermal tests with a-cyclodextrin (0.01% aq. and
0.1% aq.). All of these tests produced negative reactions, indicating
that the patient was sensitized with g-cyclodextrin containing 8
glucose units. We did not carry out any intradermal tests with b-
cyclodextrin due to its insolubility in water.
Several cases of intraoperative anaphylaxis after administration
of sugammadex have been reported in the English literature.4e8
Baldo et al.4 indicated that the use of carrier molecules such as cy-
clodextrins could change the immunological or allergic behavior of
some encapsulated drugs; therefore, sugammadex-rocuronium
complexes could become the potential allergen. In contrast, several
cases9,10 in which rocuronium-induced anaphylaxis was success-
fully managed with sugammadex (sugammadex encapsulates
rocuronium molecules) have been reported. Sadleir et al.5 reported
three cases of intraoperative anaphylaxis due to sugammadex. In
two of three cases, the responses produced during skin test of a
mixture of rocuronium and sugammadex were signiﬁcantly atten-
uated compared with those elicited during skin tests involving
sugammadex alone. Baldo et al.4 and Sadleir et al.5 proposed that
skin tests of rocuronium, sugammadex, and rocuro-
niumesugammadex complex should be performed in patients
that suffer allergic reactions after being given sugammadex to
reverse neuromuscular block or rocuronium-induced anaphylaxis.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Responses to the intradermal test of sugammadex (0.1% aq.) (A) and g-cyclodextrin (0.1% aq.) (B) at 15 min.
Fig. 2. Chemical structures of agents used in skin tests. The structures of sugammadex (A), g-cyclodextrin (B), methyl 3-mercaptopropionate (C), ethyl 3-methylthiopropionate (D),
a-cyclodextrin (E), and b-cyclodextrin (F) are shown.
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suffered sugammadex-associated hypersensitivity5,6 had previ-
ously been exposed to sugammadex. Tsur et al.7 reported that
12 cases out of 15 cases that suffered sugammadex-associatedhypersensitivity had not previously been exposed to suggama-
dex. Cyclodextrins are used as a carrier and stabilizer for ﬂavors,
colors, fat-soluble vitamins, and polyunsaturated fatty acids.3
This suggests that the above patients might have become
Letter to the Editor / Allergology International 65 (2016) 356e358358possibly sensitized to the cyclodextrins included in foods or daily
goods although they had no history of allergy for foods contain-
ing cyclodextrins. To the best of our knowledge, this is the ﬁrst
report about anaphylaxis caused by the g-cyclodextrin in sugga-
madex. Clinicians that use sugammadex should be aware that it
is possible for patients to suffer g-cyclodextrin-induced
anaphylaxis.Conﬂict of interest
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